OMER OMEROS CORP

Nasdaq Pharmaceutical Preparations WA CIK: 0001285819
AI RATING
STRONG_SELL
92% Confidence

Investment Thesis

Omeros faces critical solvency challenges with negative stockholders equity of -$63.3M and insufficient cash reserves ($1.9M) relative to operational cash burn (-$14.5M). Core business operations are deeply unprofitable with $17.4M operating losses on only $9.9M revenue, while the positive net income appears driven by non-operating gains masking fundamental operational distress. With minimal liquidity runway and substantial debt obligations ($87.9M), the company faces imminent refinancing pressures and potential dilutive capital raises.

Strengths

  • + Positive net income of $56.1M suggests access to non-operating gains or strategic asset monetization
  • + Total assets of $286.2M provide some balance sheet cushion for potential restructuring
  • + Current ratio of 3.03x indicates near-term working capital for immediate obligations

Risks

  • ! Negative stockholders equity of -$63.3M indicates technical insolvency and balance sheet deterioration
  • ! Critical cash burn: $1.9M cash with -$14.5M annual operating cash flow creates 1-2 month runway risk
  • ! Operations unviable: -$176.1% operating margin with $9.9M revenue insufficient to support $17.4M operating losses
  • ! Debt servicing unsustainable: $87.9M debt cannot be supported by negative operating cash flow; interest coverage of -0.8x
  • ! Non-operating gains masking operational failure and likely unsustainable in future periods
  • ! High probability of dilutive equity financing, covenant violations, or restructuring

Key Metrics to Watch

Financial Metrics

Revenue
9.9M
Net Income
56.1M
EPS (Diluted)
$0.62
Free Cash Flow
-14.5M
Total Assets
286.2M
Cash
1.9M

Profitability Ratios

Gross Margin N/A
Operating Margin -176.1%
Net Margin 566.7%
ROE N/A
ROA 19.6%
FCF Margin -146.6%

Balance Sheet & Liquidity

Current Ratio
3.03x
Quick Ratio
3.03x
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
-0.81x
Long-term Debt
87.9M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-23T08:56:32.632923 | Data as of: 2026-03-31 | Powered by Claude AI